Published in Semin Immunopathol on November 14, 2016
Th9 cells in immunity and immunopathological diseases. Semin Immunopathol (2016) 0.76
IL-9 and Th9 cells in health and diseases-From tolerance to immunopathology. Cytokine Growth Factor Rev (2017) 0.75
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol (2008) 6.76
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol (2008) 6.41
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature (2013) 4.74
Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 4.43
Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol (2009) 3.88
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity (2007) 3.19
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity (2001) 3.08
Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol (1998) 2.97
Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science (1983) 2.91
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol (2005) 2.81
IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med (2009) 2.78
Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol (1998) 2.74
An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol (2011) 2.69
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Multiple sclerosis. J Clin Invest (2012) 2.41
IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol (1994) 2.39
Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity (2003) 2.34
Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain (2009) 2.00
IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol (2000) 1.75
Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia (2006) 1.72
Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol (1999) 1.69
Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal (2010) 1.66
The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol (2009) 1.61
A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol (1996) 1.58
The B7/CD28 costimulatory family in autoimmunity. Immunol Rev (2005) 1.57
Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology (2007) 1.54
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Notch signaling regulates antigen sensitivity of naive CD4+ T cells by tuning co-stimulation. Immunity (2015) 1.51
Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol (2010) 1.48
IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors (2004) 1.43
OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol (2012) 1.43
A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathol (2000) 1.41
Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology (1993) 1.35
Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood (2003) 1.32
Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol (2001) 1.30
Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol (2010) 1.30
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 1.27
Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity (2012) 1.24
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood (2003) 1.23
Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity (2006) 1.22
Functional and biochemical characterization of mouse P40/IL-9 receptors. J Immunol (1990) 1.21
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One (2013) 1.21
Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun (2013) 1.20
IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol (2011) 1.19
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol (2011) 1.18
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med (2014) 1.15
CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest (2001) 1.10
IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell Death Differ (2008) 1.09
Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia. Glia (2010) 1.06
Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. J Immunol (2011) 1.06
Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol (2013) 1.05
Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A (2014) 1.05
IL-9 is a Th17-derived cytokine that limits pathogenic activity in organ-specific autoimmune disease. Eur J Immunol (2011) 1.04
IL-9 is important for T-cell activation and differentiation in autoimmune inflammation of the central nervous system. Eur J Immunol (2011) 1.01
Heteromerization of the gammac chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis. J Biol Chem (1998) 0.99
IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma. J Clin Immunol (2011) 0.94
IFN-γ limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol (2012) 0.94
Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. J Rheumatol (2009) 0.91
IL-9-induced expansion of B-1b cells restores numbers but not function of B-1 lymphocytes in xid mice. J Immunol (2004) 0.89
BCL6 controls Th9 cell development by repressing Il9 transcription. J Immunol (2014) 0.89
Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol (2012) 0.89
Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol (2003) 0.87
Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9. Respir Res (2005) 0.85
Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses. Immunology (2014) 0.80
T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis. Clin Sci (Lond) (2015) 0.79
IL-9 signaling affects central nervous system resident cells during inflammatory stimuli. Exp Mol Pathol (2015) 0.78
Rescue of human T cells by interleukin-9 (IL-9) from IL-2 deprivation-induced apoptosis: correlation with alpha subunit expression of the IL-9 receptor. J Interferon Cytokine Res (2000) 0.78
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurol (2013) 0.77
IL-9, a local growth factor for synovial T cells in inflammatory arthritis. Cytokine (2016) 0.77
Interleukin-9 receptor alpha chain mRNA formation in CD8+ T cells producing anti-human immunodeficiency virus type 1 substance(s). Acta Virol (1998) 0.76
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev Clin Immunol (2016) 0.76